Posted by Michael Wonder on 12 Jul 2021
CMS opens national coverage determination analysis on treatment for Alzheimer’s disease
12 July 2021 - Today, the Centers for Medicare & Medicaid Services is opening a National Coverage Determination analysis, a process that will allow the agency to carefully review and determine whether Medicare will establish a national Medicare coverage policy for monoclonal antibodies targeting amyloid for the treatment of Alzheimer’s disease.
National Coverage Determinations are program instructions developed by the Centers for Medicare & Medicaid Services to describe the nationwide conditions for Medicare coverage for a specific item or service.
